Skip to main content
. 2021 Nov 22;2021(11):CD004407. doi: 10.1002/14651858.CD004407.pub5

Summary of findings 13. Safety: Henoch‐Schönlein purpura.

Safety: Henoch‐Schönlein purpura
Patient or population: children 9 months to 15 years old
Setting: general population
Intervention: MMR vaccine
Comparison: unvaccinated
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI) № of participants
(studies) Certainty of the evidence
(GRADE)
Risk of HSP amongstunvaccinated Risk of HSPamongst vaccinated
Case‐control ‐ MMR vaccine Study population OR 3.40
(1.18 to 9.81) 288 cases, 617 controls
(1 observational study) ⊕⊕⊝⊝
LOW
0 per 1000 0 per 1000
(0 to 0)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HSP: Henoch‐Schönlein purpura; MMR: measles, mumps, rubella vaccine; OR: odds ratio
GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.